Related Experiment Video
Updated: Jun 1, 2026

Implantation of Left Ventricular Assist Device (LVAD) in Juvenile Landrace Swine: A LVAD Implantation Model of Pediatric Heart Failure
Published on: January 16, 2026
In vivo evaluation of the "TinyPump" as a pediatric left ventricular assist device
Takashi Kitao1, Yusuke Ando, Masaharu Yoshikawa
1Department of Artificial Organs, Tokyo Medical and Dental University, Tokyo.
Insights
A miniature rotary centrifugal blood pump, the TinyPump, was evaluated in a pediatric animal model for its potential as a pediatric left ventricular assist device (LVAD). Modified designs minimized hemolysis and thrombosis, showing promise for neonates and infants requiring mechanical circulatory support.
Area of Science:
- Biomedical Engineering
- Pediatric Cardiology
- Medical Devices
Background:
- Pediatric patients with end-stage heart failure need mechanical circulatory support (MCS).
- Existing devices often do not meet the specific requirements for neonates and infants, such as small size, low priming volume, and biocompatibility.
- The
- TinyPump
- is a miniature rotary centrifugal blood pump designed to address these needs.
Purpose of the Study:
- To evaluate the biocompatibility and hemodynamic performance of the
- TinyPump
- as a potential left ventricular assist device (LVAD) for neonates and infants.
- To assess the feasibility of using the TinyPump in a pediatric animal model.
Main Methods:
- The TinyPump, a miniaturized centrifugal pump (5 mL priming volume), was implanted in 22 Shiba goats (8.4–27.2 kg body weight).
- Implantations involved connecting the pump to the left ventricular apex and descending aorta.
- Hemodynamic parameters, blood components, and organ functions were monitored post-implantation across acute, subchronic, and chronic phases (up to 16 days).
Main Results:
- Initial experiments faced challenges with hemolysis and thrombi formation at the impeller bearing.
- Modifications to the bearing design, pump housing, and magnetic coupling significantly reduced hemolysis and thrombi.
- The modified TinyPump achieved prolonged survival in Shiba goats up to 2 weeks with minimal adverse effects on blood and organ function.
Conclusions:
- The TinyPump demonstrates feasibility as a circulatory support device for pediatric patients.
- Further improvements in durability and hemocompatibility are needed for clinical application.
- The TinyPump shows potential for bridging neonates and infants to heart transplantation or recovery.
Abstract:
Pediatric patients with end-stage heart failure require mechanical circulatory support (MCS) just as adults do. In order to meet the special requirements for neonates' and infants' MCS, pediatric circulatory support devices must be compact with low priming volume, easily controllable with low flow, less traumatic for blood cells and tissues, and biocompatible with minimum anticoagulation. We have designed and developed a miniature rotary centrifugal blood pump, "TinyPump," with a priming volume of 5 mL, which has already demonstrated its controllable performance for low flow and durability in vitro. To evaluate the feasibility of the TinyPump as a left ventricular assist device (LVAD) suitable for neonates and infants, we have examined the biocompatibility and hemodynamic performance of the TinyPump in a pediatric animal model using Shiba goats. The TinyPump is a miniaturized centrifugal pump weighing 150 g comprising a disposable pump head with a 30-mm diameter impeller having six straight-vanes and a reusable motor driver. The impeller in the pump head is supported by a hydrodynamic bearing at its center and is driven by radial magnetic force coupled to the motor driver. TinyPump implantations were performed in 22 Shiba goats (17 female and 5 male), with body weights ranging from 8.4 to 27.2 kg. Under gas anesthesia, via left lateral thoracotomy, a 22 Fr inflow cannula was inserted through the left ventricular apex, while a 6-mm outflow graft was anastomosed to the descending aorta, which were then connected to a TinyPump mounted on the animal's back. Postoperative hemodynamic monitoring included heart rate, arterial and central venous pressure, pump flow, and rotation speed. Target pump flow in all animals was maintained at 0.9 ± 0.1 L/min, which is approximately half the normal pulmonary artery flow measured in control animals. Blood samples were collected to evaluate peripheral organ functions, hemolysis, and thrombosis. Goats were divided into three groups-acute phase (6 h; n = 4), subchronic phase (6 h 2 postoperative days [POD]; n = 11), and chronic phase (3 POD-16 POD; n = 8)-based on their survival duration. In the early experiments, hemolysis and thrombi formation at the impeller bearing resulted in termination of the study. Subsequent modifications of the bearing design, pump housing design, and magnetic coupling force helped to minimize the hemolysis and thrombi formation, prolonging the survival duration of the Shiba goats to 2 weeks with minimum adverse effects on the blood components and organ functions. With further experiments and improvements in pump durability and hemocompatibility, the TinyPump can serve as a suitable circulatory support device for neonates and infants bridging to heart transplantation as well as to heart recovery.
